The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to more affordable alternatives to brand-name drugs—including blockbusters ...
FTC targets 300 Big Pharma 'junk patents,' sends warning letters to top drugmakers The agency has stepped up its campaign against drugmakers' improper listing of patents in the FDA's Orange Book ...
The US Federal Trade Commission (FTC) has expanded its campaign against so-called ‘junk’ patents intended to extend market exclusivity and block generic rivals. The financial regulator has ...
What Happened: The FTC is disputing “junk patent listings” for diabetes, weight loss, asthma and COPD drugs. This initiative represents the latest endeavor against what the agency perceives as ...
The FTC recently announced that it has sent another round of letters disputing additional patent listings in the FDA’s Orange Book. With this latest action, the FTC has now challenged hundreds ...
The U.S. Federal Trade Commission expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings pertaining to 20 different brand-name treatments for ...
On April 30, 2024, the Federal Trade Commission (FTC) announced that it sent a new set of warning letters to ten pharmaceutical companies. The letters inform the companies that the FTC has ...
The US Federal Trade Commission (FTC) revealed on Friday that it has filed an amicus brief explaining that pharmaceutical maker Teva Pharmaceutical Industries (NYSE: TEVA) has improperly listed ...
AIDS Healthcare Foundation (AHF) voiced support for the U.S. Federal Trade Commission (FTC) taking action this week to challenge several major pharmaceutical companies, including GSK, for ...